Match!
Norbert Stefan
University of Tübingen
EndocrinologyInsulin resistanceInsulinDiabetes mellitusMedicine
392Publications
64H-index
13.9kCitations
What is this?
Publications 389
Newest
#1Norbert StefanH-Index: 64
Last. David S. Ludwig (Harvard University)H-Index: 66
view all 4 authors...
Preliminary data suggest that people with obesity are at increased risk of severe COVID-19. However, as data on metabolic parameters (such as BMI and levels of glucose and insulin) in patients with COVID-19 are scarce, increased reporting is needed to improve our understanding of COVID-19 and the care of affected patients.
3 CitationsSource
#1Sabine Kahl (HHU: University of Düsseldorf)H-Index: 7
#2Sofiya Gancheva (HHU: University of Düsseldorf)H-Index: 3
Last. Michael Roden (HHU: University of Düsseldorf)H-Index: 69
view all 24 authors...
OBJECTIVE To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnet...
2 CitationsSource
#1Norbert Stefan (University of Tübingen)H-Index: 64
#2Michael Roden (HHU: University of Düsseldorf)H-Index: 18
Last. Michael Roden (HHU: University of Düsseldorf)H-Index: 3
view all 2 authors...
Source
#1Norbert Stefan (University of Tübingen)H-Index: 64
#2Michael Roden (HHU: University of Düsseldorf)H-Index: 69
Source
Source
#1Elko Randrianarisoa (University of Tübingen)H-Index: 6
#2Angela Lehn-Stefan (University of Tübingen)H-Index: 7
Last. Harald Staiger (University of Tübingen)H-Index: 41
view all 10 authors...
Source
#2Olga KuxhausH-Index: 5
Last. Matthias B. Schulze (University of Potsdam)H-Index: 71
view all 5 authors...
Aims/hypothesis This study aimed to evaluate associations of height as well as components of height (sitting height and leg length) with risk of type 2 diabetes and to explore to what extent associations are explainable by liver fat and cardiometabolic risk markers.
3 CitationsSource
#1Elko Randrianarisoa (University of Tübingen)H-Index: 6
#2Angela Lehn-Stefan (University of Tübingen)H-Index: 7
Last. Kilian RittigH-Index: 21
view all 10 authors...
1 CitationsSource
#1Hans Hauner (TUM: Technische Universität München)H-Index: 50
#2Anja MossH-Index: 12
Last. Martin TeufelH-Index: 22
view all 12 authors...
1 CitationsSource
#1Sabine KahlH-Index: 7
#2Sofiya GanchevaH-Index: 3
Last. Michael RodenH-Index: 69
view all 18 authors...
Type 2 diabetes (T2D) associates with nonalcoholic fatty liver disease (NAFLD), which itself contributes to both insulin resistance and excessive cardiovascular risk of diabetes. Nevertheless, there is currently no established therapy for NAFLD in T2D. This trial examined whether treatment with the sodium glucose transporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (HCL, primary outcome) in metabolically well-controlled patients with short known disease duration. T2D patients (...
Source
12345678910